Equities research analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Up 1.9 %
Shares of NASDAQ:AKTX opened at $3.22 on Monday. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $4.40. The firm has a fifty day moving average price of $3.60 and a 200 day moving average price of $2.59.
About Akari Therapeutics
See Also
- Five stocks we like better than Akari Therapeutics
- How to Calculate Inflation Rate
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- What is a Death Cross in Stocks?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What is a Secondary Public Offering? What Investors Need to Know
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.